Effects of fibrates in kidney disease: a systematic review and meta-analysis
about
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapyAlteration of Fatty Acid Oxidation in Tubular Epithelial Cells: From Acute Kidney Injury to Renal FibrogenesisDiabetic kidney disease: a report from an ADA Consensus ConferenceMetabolic syndrome in children with chronic kidney disease and after renal transplantationClinical therapeutic strategies for early stage of diabetic kidney disease.The impact of antihypertensives on kidney disease.Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients.Association of uric acid, atherogenic index of plasma and albuminuria in diabetes mellitus.Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidenceMolecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolismFenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study.Demystifying the management of hypertriglyceridaemia.Lipid mediators in diabetic nephropathy.Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.Dyslipidemia in patients with chronic kidney disease.The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.Liver Transplantation: the Role of Metabolic Syndrome.Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development.Lipid lowering in renal disease.Diabetic kidney disease.Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ ligands against methotrexate-induced nephrotoxicity.Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min).Patterns of progression of chronic kidney disease at later stages.KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease
P2860
Q24616813-063D62D1-4B3E-49A0-8806-AF5DE25F819FQ26798068-05F766E0-B8E0-4DB4-8646-270BA669B4F0Q27012546-CC9165D7-04D1-44EB-8D76-CC354B48FAA4Q27027049-989D85D1-C9FD-47B0-A7C6-5B046CB32D55Q30363683-F964743D-3442-43DD-BC39-398C4DA069CFQ33632021-97D1787D-1612-4F47-92FC-45A503D9A7AFQ33776176-EA96383B-7E62-4A92-B285-AE81C9E532DFQ33776194-AEFDF045-A05F-4CFF-AE4C-FB99255D98CEQ33776230-FE84B0D4-EEE8-4482-979A-F17D56BECEB3Q33783149-044C6F2C-D079-41FB-ABAE-C4CD265A44E1Q35017383-C68695A9-4668-48FD-A4CE-EF0919F0DAE6Q35492306-D64F2EF3-602C-445C-97FE-557BEC54A7A2Q37254899-08B4FAD8-1609-493F-A760-C4F3F4E22F7BQ37651950-D558E86E-6985-4FB5-98B2-5558DDF0A9A2Q37681585-5BA154EE-3C88-4B01-86CD-49A200A56DF4Q38141575-F3CFE304-0A58-444A-9E33-E47464F85D62Q38248011-BCEBF0B5-8790-4C9B-AFBE-5DF7EB268A09Q38553332-83852672-C04F-43AB-96E1-B3ECF318F4ECQ38629322-4EB9A23B-9C83-488F-B8B7-D4DBB85DF941Q39045120-5339CCDF-E019-4F1B-AE25-15008CBBFF40Q39185669-65DC3687-3366-45E6-8194-A8A44C3634CEQ39255762-A18108D9-8E69-4961-A5C6-11D7AA6D7A99Q41088301-3748D823-B00B-4D95-946F-6BF87E4993FDQ41690923-3917A05B-202C-4FD2-8B5F-FF7955CD74ACQ43721013-49F94198-F6C0-45EB-A3AB-9E1693F27693Q46661140-44AFB9E5-AFC3-4C10-BA6A-764E19B6A964Q46945180-1883B990-887D-43C6-85CD-CE06D08E3233Q48662036-17FFE500-6394-40DC-8FC7-88241963BF2CQ49908584-C040474A-25CB-4535-8AED-C07F83C6ACFFQ53519441-354BAA6A-5693-4BC3-AC70-68AFA131B29FQ55000470-5D20A6F9-F135-4B1C-8788-2A038D7647EBQ59167464-BA559A4C-D192-42D3-897B-4B32593A4F24
P2860
Effects of fibrates in kidney disease: a systematic review and meta-analysis
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@ast
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@en
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@nl
type
label
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@ast
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@en
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@nl
prefLabel
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@ast
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@en
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@nl
P2093
P31
P50
P1476
Effects of fibrates in kidney disease: a systematic review and meta-analysis
@en
P2093
Anthony Keech
Anushka Patel
Thaminda Liyanage
P304
P356
10.1016/J.JACC.2012.07.049
P407
P577
2012-10-17T00:00:00Z